S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
prostate cancer before repeat biopsy. Eur Radiol 2009;19(3):770-8.
http://www.ncbi.nlm.nih.gov/pubmed/18925403
67. Labanaris AP, Engelhard K, Zugor V, Nutzel R, Kuhn R. Prostate cancer detection using an
extended prostate biopsy schema in combination with additional targeted cores from
suspicious images in conventional and functional endorectal magnetic resonance imaging
of the prostate. Prostate Cancer Prostatic Dis 2010;13(1):65-70.
http://www.ncbi.nlm.nih.gov/pubmed/19752886
68. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone
A, Bernardo S, Passariello R, Gentile V. Value of magnetic resonance spectroscopy imaging
and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with
prior negative biopsy. Clin Cancer Res 2010;16(6):1875-83.
http://www.ncbi.nlm.nih.gov/pubmed/20197480
69. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT. Prostate cancer: detection
of extracapsular extension by genitourinary and general body radiologists at MR imaging.
Radiology 2004;232(1):140-6. http://www.ncbi.nlm.nih.gov/pubmed/15166319
70. Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, Stief C, Hricak H, Graser
A. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009;55(4):801-14.
http://www.ncbi.nlm.nih.gov/pubmed/19185981
71. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and
radioactively labeled choline derivates. Urol Oncol 2011.
http://www.ncbi.nlm.nih.gov/pubmed/21388835
72. Sobin LH, Gospodarowicz MK, Wittekind C, (eds.). TNM Classification of Malignant Tumours.
7th ed. Hoboken: Wiley-Blackwell; 2009.
73. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski
JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical
prostatectomy, external beam radiation therapy, or interstitial radiation therapy for
clinically localized prostate cancer. JAMA 1998;280(11):969-74.
http://www.ncbi.nlm.nih.gov/pubmed/9749478
74. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV,
Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR,
Moul JW, Tangen CM. Guideline for the management of clinically localized prostate cancer:
2007 update. Journal of Urology 2007;177(6):2106-31.
http://www.ncbi.nlm.nih.gov/pubmed/17509297
75. Manikandan R, Qazi HA, Philip J, Mistry R, Lamb GH, Woolfenden KA, Cornford PA, Parsons
KF. Routine use of magnetic resonance imaging in the management of T(1c) carcinoma of
the prostate: is it necessary? J Endourol 2007;21(10):1171-4.
http://www.ncbi.nlm.nih.gov/pubmed/17949319
76. Nogueira L, Wang L, Fine SW, Pinochet R, Kurta JM, Katz D, Savage CJ, Cronin AM, Hricak H,
Scardino PT, Akin O, Coleman JA. Focal treatment or observation of prostate cancer:
pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology
2010;75(2):472-7. http://www.ncbi.nlm.nih.gov/pubmed/19643467
77. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, Khurana K, Ravizzini GC,
Albert PS, Merino MJ, Choyke PL. Prostate cancer: value of multiparametric MR imaging at 3
T for detection--histopathologic correlation. Radiology 2010;255(1):89-99.
http://www.ncbi.nlm.nih.gov/pubmed/20308447
78. Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotto CK, Cho H, Kawashima A,
Tempany-Afdhal CM, Macura KJ, Rosen M, Gerst SR, Kurhanewicz J. Prostate cancer: sextant
localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011